When Lyophilization Cycle Parameters Shift Beyond Collapse Temperature

In the manufacture of lyophilized injectable presentations, Pseudorabies vaccine veterinary grade API is processed either as live attenuated or inactivated viral antigen, but the freeze-drying step is most critical for the live attenuated platform because the enveloped herpesvirus particle is destroyed by uncontrolled ice-crystal growth and osmotic shock. Freeze-drying cycles for this class of enveloped veterinary virus are built around the collapse temperature of the formulated product, commonly −32 °C to −28 °C for sucrose- or trehalose-stabilized matrices; a primary drying shelf temperature set more than 2–4 °C above formulation collapse temperature produces macro-collapse, high residual moisture, and sharp loss of virus titre. Production-scale lyophilizers require controlled nucleation or annealing when mannitol or glycine is included because crystalline bulking agents alter the glass transition profile of the frozen matrix and reduce cycle robustness. The freezing step is typically performed at −45 °C to −50 °C with shelf cooling rates of 0.5–1.0 °C/min, followed by an annealing step at −10 °C to −5 °C where crystalline excipients are allowed to ripen. Chamber pressure is normally maintained between 50 µbar and 150 µbar during primary drying, and secondary drying is executed at 20 °C to 25 °C until Karl Fischer residual moisture falls below 2.0% as measured according to Ph. Eur. 2.5.12. Product-contact surfaces of the lyophilizer, including stainless steel shelf coils and silicone oil thermal fluid circuits, require validated sterilization and filter integrity testing following ISO 13408-1:2023 and ISO 14644-1:2015 Class 5 environmental monitoring. Excipient selection for injectable presentations generally includes trehalose dihydrate at 3.0–5.0% w/v, hydrolyzed gelatin at 1.0–2.0% w/v, and phosphate or tris buffer at pH 7.0–7.4; sorbitol and mannitol may be added but require annealing because of crystalline phase separation. The inactivated injectable presentations are more forgiving in lyophilization and more frequently processed as liquid suspensions, whereas the live attenuated API is sold as a freeze-dried cake that is reconstituted with sterile diluent shortly before intramuscular injection. Batch-to-batch variance on commercial lyophilization lines is controlled by measuring collapse temperature via freeze-dry microscopy and by recording the Pirani versus capacitance manometer pressure differential during primary drying; published data for this specific Pseudorabies antigen-lot formulation remain limited, so cycle parameters must be developed for each antigen strain and excipient matrix.

Feed-path administration of live attenuated Pseudorabies vaccine API places a completely different set of constraints on the excipient matrix than injectable presentations, because the virus must survive mechanical shear, feed mixing, and the low pH of the porcine stomach before reaching intestinal lymphoid tissue. Oral premix and coated granule systems for this antigen are most realistically prepared as microspheres or pellets with core diameters of 0.8–1.5 mm, coated with enteric polymers such as Eudragit L30 D-55 or cellulose acetate phthalate that begin dissolution above pH 5.5; uncoated granules are not considered a viable oral presentation for live enveloped virus because infectivity is reduced by several log units below pH 3.0. Fluidised-bed coating using a Wurster insert is the most frequently cited method for applying enteric films without exposing the antigen to excessive thermal load, with inlet air temperature held below 55 °C, product temperature below 35 °C, and spray rate adjusted to maintain a relative humidity below 60% in the expansion chamber. Coating efficiency on production-scale equipment typically falls between 85% and 95%, and the remaining spray-dried polymer fine fraction must be separated because it contains no antigen and creates static charge in downstream blending. Twin-screw extrusion for bait pellets is limited by the heat lability of the enveloped herpesvirus; barrel temperature settings above 50 °C are generally unacceptable unless the formulation includes a high level of protective sucrose, gelatin, and low-moisture starch at water activity below 0.30. Published data for oral Pseudorabies vaccine premix under commercial pelletizing conditions are limited; most peer-reviewed studies describe experimental bait matrices containing alginate-calcium chloride gel encapsulation rather than standard feed granulation. Batch release of an oral premix should include virus titration in cell culture, pH-release testing of the coating, and blend uniformity acceptance criteria aligned with Ph. Eur. 2.9.5 and USP <905>, with the concentration of active antigen expressed as TCID₅₀ per gram of final premix.

Why Does Direct Compression Destabilize Live Herpesviral Antigen More Than Roller Compaction?

Tablet and capsule manufacture using live attenuated Pseudorabies vaccine API introduces a dry-state destructive stress that is absent in liquid or freeze-dried presentations: tablet compression imposes local pressure increases and die-wall friction, both of which can rupture the viral envelope and reduce titre. Direct compression is therefore more damaging than dry granulation by roller compaction, because direct compression requires higher lubricant and brittle filler loadings and generates greater shear in the die; roller compaction consumes energy in the nip region but produces a granular intermediate that can be compressed at substantially lower final compaction stress. Capsule filling is less stressful than tableting for this antigen because the filled powder bed is not compressed into a compact; hydrophobic HPMC capsules with lock-ring closures are preferred over gelatin because the gelatin shell absorbs moisture at relative humidity above 60% and may become brittle below 35%. The powder for capsule or tablet cores must be dried to water activity below 0.30 and moisture below 2.0% using vacuum drying or dry nitrogen purging before blending with microcrystalline cellulose PH101, spray-dried lactose monohydrate, and sodium starch glycolate at 2–4% w/w as disintegrant. Tablet hardness should remain at 4–7 kp on a Schleuniger tester, and friability should not exceed 1.0% after 100 rotations under Ph. Eur. 2.9.7; harder compacts may delay disintegration but do not automatically preserve viral titre, because the initial compaction event is the main source of mechanical inactivation. Enteric tablet coating is required for oral application because of gastric acid lability; the coating thickness should be controlled gravimetrically at 8–12% weight gain and tested by two-stage dissolution at 0.1 N HCl for 2 h followed by phosphate buffer at pH 6.8 according to Ph. Eur. 2.9.3 or USP <711>. Blending of the antigen with excipients must avoid magnesium stearate levels above 0.5–1.0% w/w because hydrophobic particle coatings can delay dissolution and prolong residence time in the stomach after gastric emptying begins. Published data for commercial Pseudorabies vaccine tablets and capsules are limited; the technical constraints described here are derived from general viral vaccine dry-formulation literature and require strain-specific process validation.

Liquid presentations of inactivated Pseudorabies antigen differ from live freeze-dried presentations in that the aqueous or emulsified adjuvant system controls antigen presentation and local irritation after intramuscular injection. A conventional aqueous suspension is prepared by diluting the antigen concentrate into phosphate-buffered saline at pH 7.0–7.4 with 0.01% w/v thiomersal or 0.2% w/v phenoxyethanol as preservative, provided the inactivating chemistry and preservative do not further denature the viral glycoproteins. Aluminium hydroxide adjuvant is commonly used at a final aluminium concentration of 0.5–2.0 mg/mL, and oil-in-water emulsions are prepared by high-shear homogenisation at rotor-stator speeds of 10 000–15 000 rpm followed by microfluidisation at 500–1 500 bar; the finished emulsion should pass droplet-size analysis by laser diffraction with a D₅₀ below 0.5 µm. Unlike live attenuated solutions, inactivated antigen liquids may be filtered through 0.45 µm or 0.22 µm membranes before aseptic filling, but filtration can reduce antigen recovery because the antigen may be present as fragments or adsorbed to aluminium gel. Aseptic filling lines for multi-dose vials operate under ISO 13408-1:2023 using isolator or restricted access barrier technology, with settle plates and active air sampling maintained according to ISO 14644-1:2015 Class 5. Live attenuated Pseudorabies API in liquid form is rarely presented as a ready-to-use solution because the enveloped particle loses infectivity in aqueous media within hours at 20–25 °C; therefore, liquid solutions are essentially limited to inactivated antigen platforms or diluents that accompany lyophilized cakes. For intranasal or conjunctival administration of live attenuated strains, the lyophilized cake is reconstituted in a preservative-free sterile diluent supplied in a separate container, and product use after reconstitution is restricted to 2–4 h at 2–8 °C to limit titre loss. Published stability data for a specific Pseudorabies vaccine veterinary grade API in all liquid and emulsion configurations are limited, and container-closure compatibility must be studied using Ph. Eur. 3.2.2 plastic materials or Type I glass.

Powder and Granule Blending Limits in Swine Feed Premix Lines

Dry powder blending of a live attenuated Pseudorabies vaccine API into swine feed premix lines operates under a strict carry-over prevention logic, because trace quantities of viral antigen in conventional feed mills are biologically active and can expose non-target animals. A cGMP veterinary biologics premix is generally manufactured by stepwise geometric dilution in a Lödige plowshare mixer or a stainless-steel ribbon blender with a finished batch coefficient of variation below 5.0% for the tracer used during validation. The API is first pre-blended with lactose monohydrate or maltodextrin at a 1:10 ratio, then 1:100, and finally incorporated into a carrier premix at 2 000–5 000 g/T where 1 T equals 1 000 kg of final feed. Feed mills that process both medicated and non-medicated lines must segregate the Pseudorabies vaccine premix from cross-contamination by washing contact surfaces with 1.0% sodium hypochlorite or a validated alkaline detergent, and by maintaining a dedicated vacuum system because airborne dust can contain antigen-loaded fines below 50 µm. High-shear granulation of the API into compacted granules is sometimes used to reduce dust and improve flow, but the wet granulation step requires an inlet air temperature below 45 °C and drying to a final residual moisture below 2.0%; organic solvents must be avoided because the viral envelope is solvent-sensitive. Roller compaction at hydraulic pressure between 20 bar and 60 bar is less destructive than direct tableting and has been evaluated for oral veterinary vaccine granules, although published data for this specific Pseudorabies antigen in roller compaction are limited. The final premix should be filled into multi-wall paper bags with an inner low-density polyethylene liner and stored at 2–8 °C; freeze-thaw cycles below −20 °C may damage the live antigen unless protected by a freeze-stable carrier. Quality control for such powder premix operations includes viral titre per gram, moisture by Karl Fischer, blend uniformity, and extraneous agent testing according to Ph. Eur. 2.6.16 and relevant USDA 9 CFR Part 113 requirements.